Jarocki Michał, Karska Julia, Kowalski Szymon, Kiełb Paweł, Nowak Łukasz, Krajewski Wojciech, Saczko Jolanta, Kulbacka Julita, Szydełko Tomasz, Małkiewicz Bartosz
University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland.
J Clin Med. 2022 Aug 24;11(17):4973. doi: 10.3390/jcm11174973.
Nowadays, molecular and immunological research is essential for the better understanding of tumor cells pathophysiology. The increasing number of neoplasms has been taken under 'the molecular magnifying glass' and, therefore, it is possible to discover complex relationships between the cytophysiology and immune system action. An example could be renal cell carcinoma (RCC) which has deep interactions with immune mediators such as Interleukin 17 (IL-17)-an inflammatory cytokine reacting to tissue damage and external pathogens. RCC is one of the most fatal urological cancers because of its often late diagnosis and poor susceptibility to therapies. IL-17 and its relationship with tumors is extremely complex and constitutes a recent topic for numerous studies. What is worth highlighting is IL-17's dual character in cancer development-it could be pro- as well as anti-tumorigenic. The aim of this review is to summarize the newest data considering multiple connections between IL-17 and RCC.
如今，分子和免疫学研究对于更好地理解肿瘤细胞病理生理学至关重要。越来越多的肿瘤已被置于“分子放大镜”之下，因此，有可能发现细胞生理学与免疫系统作用之间的复杂关系。一个例子是肾细胞癌（RCC），它与免疫介质如白细胞介素17（IL-17）有深入的相互作用，IL-17是一种对组织损伤和外部病原体起反应的炎性细胞因子。由于肾细胞癌常常诊断较晚且对治疗的敏感性较差，它是最致命的泌尿系统癌症之一。IL-17及其与肿瘤的关系极其复杂，是众多研究的一个新课题。值得强调的是IL-17在癌症发展中的双重特性——它既可能是促肿瘤的，也可能是抗肿瘤的。这篇综述的目的是总结关于IL-17与肾细胞癌之间多种联系的最新数据。
